{name}
{subtitle}
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
city
~22 mi. (Rimini, Italy, +383 more cities)
facility
Ospedale degli Infermi
biomarker
ER Negative, +2 more biomarkers
drug
atezolizumab, +4 more drugs
drug type
chemotherapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~51 mi. (Meldola, Italy, +226 more cities)
facility
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Oncologia Medica ( Site 0464)
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
city
~51 mi. (Meldola, Italy, +262 more cities)
facility
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
biomarker
ER Positive, +1 more biomarker
drug
giredestrant, +2 more drugs
drug type
hormone therapy, +1 more type
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
city
~51 mi. (Meldola, Italy, +131 more cities)
facility
Istituto Scientifico Romagnolo per Studio e Cura Tumori IRST ( Site 1608)
drug
CAPOX regimen, +3 more drugs
drug type
chemotherapy, +2 more types
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
city
~51 mi. (Meldola, Italy, +141 more cities)
facility
GSK Investigational Site
drug type
chemotherapy, +1 more type